Genomics of Drug Sensitivity in Cancer |
BAY-61-3606
|
Synonyms |
Syk Inhibitor, BAY-613606
|
Targets |
SYK
|
Target pathway |
Other, kinases
|
PubCHEM ID |
10200390
|
Jsmol |
|
Download molecule |
10200390
|
PUBCHEM IUPAC INCHI |
InChI=1S/C20H18N6O3/c1-28-15-6-5-12(10-16(15)29-2)14-11-17-22-8-9-26(17)20(24-14)25-19-13(18(21)27)4-3-7-23-19/h3-11H,1-2H3,(H2,21,27)(H,23,24,25)
|
Smiles |
O=C(N)C1(=C(N=CC=C1)NC3(=NC(C2(=CC(OC)=C(OC)C=C2))=CC=4(N3C=CN=4)))
|
Cluster number |
85
|
calculated LogS |
-6,17
|
Molecular weight |
390,402
|
calculated LogP |
1,9877
|
H-Acceptors |
9
|
H-Donors |
2
|
Ro5 violations |
0
|
Druglikeness |
2,7802
|
DrugScore |
0,524260937047251
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
Low FHMT
|
Fish Toxicity2 |
1,465
|
Rat Acute Toxicity |
2,481
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2+
|
Caco-2 Permeability2 |
1,3327
|
P-glycoprotein Substrate |
Non-substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,4607
|
AMES Toxicity |
AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Danger
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,3313
|